Sinocelltech's subsidiary product SCT640C has received approval for clinical drug trials

Zhitong
2025.07.24 08:05
portai
I'm PortAI, I can summarize articles.

According to the Zhitong Finance APP, Sinocelltech announced that recently, its holding subsidiary, Beijing Sinocelltech Biotechnology Group Co., Ltd. (hereinafter referred to as "the Company"), received the "Drug Clinical Trial Approval Notice" approved and issued by the National Medical Products Administration (hereinafter referred to as "NMPA"), agreeing to conduct clinical trials for the product SCT640C injection developed by the Company for the indication of adult rheumatoid arthritis

According to the Zhitong Finance APP, Sinocelltech (688520.SH) announced that recently, its holding subsidiary, Beijing Sinocell Biotechnology Group Co., Ltd. (hereinafter referred to as "the Company"), received the "Drug Clinical Trial Approval Notice" approved and issued by the National Medical Products Administration (hereinafter referred to as "the NMPA"), agreeing to conduct clinical trials for the adult rheumatoid arthritis indication of the Company's independently developed product SCT640C injection

Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.